×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GNTA – genenta science s.p.a. - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GNTA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
10/23
07:08 am
gnta
Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" [Financial Post (Toronto, Ontario, Canada)]
10/23
07:00 am
gnta
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
Medium
Report
Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”
10/11
07:56 am
gnta
Genenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insiders [Yahoo! Finance]
High
Report
Genenta Science S.p.A.'s (NASDAQ:GNTA) market cap rose US$46m last week; individual investors who hold 55% profited and so did insiders [Yahoo! Finance]
10/2
11:20 am
gnta
Genenta Science S.p.A. (NASDAQ: GNTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Medium
Report
Genenta Science S.p.A. (NASDAQ: GNTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
10/2
06:36 am
gnta
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer [Financial Post (Toronto, Ontario, Canada)]
10/2
06:30 am
gnta
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Medium
Report
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: